Evidence map›Paper›PMID 33846559›Full record

ArticleBone marrow transplantation2021

Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study.

Yarden Greental Ness, Amir A Kuperman, Jerry Stein, Joanne Yacobovich, Ehud Even-Or, Irina Zaidman, Aharon Gefen, Neta Nevo, Bernice Oberman, Amos Toren and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yarden Greental Ness *Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Amir A Kuperman *Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.ORCID http://orcid.org/0000-0003-1873-7660
Jerry SteinHematology-Oncology Division, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel.
Joanne YacobovichHematology-Oncology Division, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel.ORCID http://orcid.org/0000-0003-3763-5694
Ehud Even-OrFaculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-4292-6376
Irina ZaidmanFaculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel.
Aharon GefenDivision of Pediatric Hematology-Oncology, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
Neta NevoDivision of Pediatric Hematology-Oncology, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
Bernice ObermanBiostatistics & Biomathematics, The Gertner Institute for Epidemiology and Health Policy Research, Tel Aviv, Israel.
Amos TorenSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Polina StepenskyFaculty of Medicine, Hebrew University of Jerusalem, Israel, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel.
Bella BieloraiSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Elad JacobySackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. elad.jacoby@sheba.gov.il.ORCID http://orcid.org/0000-0003-1411-8942
Tel Aviv University · ILHebrew University of Jerusalem · ILBar-Ilan University · ILRambam Health Care Campus · ILIsrael National Institute for Health Policy Research · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the results of national retrospective study of 45 children with hemophagocytic lymphohistiocytosis (HLH) who underwent allogeneic hematopoietic stem-cell transplantation (HSCT) in Israel between the years 2000-2018. Donors were either HLA-matched (n = 26), partially mismatched (n = 7), haploidentical (n = 8), or cord-blood (n = 4). Myeloablative conditioning (MAC) was used in 20 procedures, and reduced-intensity conditioning (RIC) in 25. Forty-two patients engrafted, two had primary graft failure (one successfully retransplanted), one died prior to engraftment, and two developed secondary graft failure. Of the eight patients who had mixed donor chimerism at day 30 (5-95%), five achieved stable mixed or full donor chimerism. The 5-year probabilities of overall survival and event-free survival (EFS) were 86% and 82%, respectively. Five-year EFS was lower for patients receiving RIC compared to MAC (72% vs. 100%, p = 0.018) and following alternative-donor transplant (68% vs. 92% for HLA-matched donors, p = 0.034), mostly due to increased transplant-related mortality (TRM). Thus, both HLA-matched and alternative donor transplant procedures may benefit form a myeloablative conditioning regimen.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphohistiocytosis, HemophagocyticHumansMyeloablative AgonistsRetrospective StudiesTransplantation ConditioningMyeloablative Agonists

Identifiers

PMID33846559
OpenAlexW3154478477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.